IgA Nephropathy Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Aravive, Aduro BioTech, Alnylam, Chinook Therapeutics, Transcenta Holding, Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics

DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the IgA Nephropathy Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual IgA Nephropathy therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current IgA Nephropathy treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

IgA Nephropathy: An Overview
IgA Nephropathy (IgAN) is an autoimmune disease that attacks the kidneys and affects blood filtration in the small blood vessels of the kidneys. It occurs when an abnormal protein damages the kidneys' filtering unit (glomerulus).

The Oxford Classification of IgA nephropathy (IgAN) is the most widely accepted system for assessing histologic findings in IgAN. The classification indicated that only three reproducible variables were seen on the renal biopsy in IgAN that independently predicted outcome and provided prognostic information in addition to prognosis prediction given by clinical features alone.

The diagnosis of IgAN relies on revealing IgA as the dominant or co-dominant immunoglobulin in the glomerular mesangium by kidney biopsy. Although renal biopsy remains the gold standard for IgAN diagnosis, recent efforts have sought new biomarkers to predict IgAN without needing a biopsy. However, unclear pathogenesis complicates noninvasive diagnosis.

Conventional major treatments to manage IgAN include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. Other treatments include corticosteroids to slow the progression of the disease and other immunosuppressants like mycophenolate mofetil (MMF), cyclophosphamide, etc.

The IgAN treatment space is estimated to experience significant changes during the forecast period, owing to the launch of upcoming novel therapies and a robust pipeline of drugs developing to manage IgAN. However, the challenges of pricing, reimbursement, and associated side effects are two major factors likely to influence the market success of the upcoming therapies.

IgA Nephropathy Market Key Facts
• Among EU4 countries, Germany accounted for the maximum market size in 2022, while Spain occupied the bottom of the ladder.
• The total number of prevalent cases of IgA Nephropathy in the United States was around ~193,700 cases in 2022.
• Among the EU4 countries, Germany accounted for the largest IgA Nephropathy prevalent cases, followed by France, whereas Spain accounted for the lowest number of prevalent cases in 2022.
• Japan accounted for about 88,000 diagnosed prevalent cases of IgA Nephropathy in 2022.
• As per DelveInsight, the IgA Nephropathy Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of IgA Nephropathy and the launch of new therapies in the market.

IgA Nephropathy Market Growth Factors and Associated Trends
The IgA Nephropathy (IgAN) market within the Seven Major Markets (7MM) is influenced by a complex interplay of drivers and barriers that significantly impact its trajectory. Drivers of growth encompass various factors, including heightened awareness and improved diagnosis rates due to advancements in diagnostic techniques and increased understanding of the disease pathology. Moreover, the rising prevalence of IgA Nephropathy, particularly among the aging population, acts as a catalyst for market expansion.

Additionally, ongoing research and development efforts aimed at identifying novel therapeutic targets and treatment modalities drive innovation within the market, offering hope for more effective management of the disease. Furthermore, the evolving treatment landscape, including the exploration of immunosuppressive agents and targeted therapies, fosters market growth by addressing the unmet medical needs of patients with IgA Nephropathy.

However, barriers persist, hindering the market's progress in the 7MM. These barriers encompass challenges in accurately diagnosing IgA Nephropathy due to its diverse clinical presentation and the absence of a definitive diagnostic test. Additionally, limited treatment options and the lack of universally accepted treatment guidelines pose significant hurdles.

Moreover, economic factors such as high treatment costs and reimbursement complexities limit patient access to effective therapies. Overcoming these barriers requires concerted efforts in research, improved diagnostic tools, the development of targeted therapies, and advancements in healthcare policies to enhance the management of IgA Nephropathy and foster market growth in the 7MM.

Get a Detailed Overview of the Evolving IgA Nephropathy Market Trends @
https://www.delveinsight.com/report-store/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

IgA Nephropathy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging IgA Nephropathy therapies in the market. It also provides a detailed assessment of the IgA Nephropathy market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed IgA Nephropathy drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the IgA Nephropathy Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

IgA Nephropathy Epidemiology
The epidemiology section covers detailed insights into the historical, and current IgA Nephropathy patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the IgA Nephropathy Epidemiology Segmented as -
• Total Prevalent Cases of IgA Nephropathy in the 7MM [2019-2032]
• Total Diagnosed Prevalent Cases of IgA Nephropathy in the 7MM [2019-2032]
• Gender-specific Cases of IgA Nephropathy in the 7MM [2019-2032]
• Age-specific cases of IgA Nephropathy in the 7MM [2019-2032]

Get Key Insights Into the Evolving IgA Nephropathy Epidemiology Trends @
https://www.delveinsight.com/report-store/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

IgA Nephropathy Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the IgA Nephropathy market or expected to be launched during the study period. The analysis covers the market share by IgA Nephropathy drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the IgA Nephropathy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the IgA Nephropathy Market @
https://www.delveinsight.com/sample-request/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

IgA Nephropathy Therapeutics Assessment
The mainstay of therapy in IgA Nephropathy is optimized supportive care, which includes measures to lower blood pressure, reduce proteinuria, reduce lifestyle risk factors, and assist in reducing non-specific kidney insult. The value of immunosuppression has become debatable; if at all, systemic high-dose corticosteroid treatment for a few months should be considered, taking into account patient characteristics that would warn against or preclude such therapy.

Furthermore, as GFR decreases, AEs associated with corticosteroid treatment significantly increase. Except for mycophenolate mofetil in Asian patients, there is little proof that any additional immunosuppression is beneficial beyond corticosteroids.

There are only two FDA-approved treatments for managing IgAN. Though recent drug approvals provide novel treatment choices for IgAN, there is still a high demand in the IgAN therapeutic landscape for more efficacious and targeted therapies. According to DelveInsight, the IgAN treatment space will undergo significant changes during the forecast period, due to the launch of upcoming novel therapies and a robust pipeline of drugs in development for the treatment of IgAN.

Improved understanding of the underlying molecular pathways responsible for IgAN has led to better therapies targeting novel pathways. The major pharma players currently developing therapies for IgAN include Omeros Corporation (narsoplimab), Novartis Pharmaceuticals (iptacopan), Otsuka Pharmaceutical (sibeprenlimab), RemeGen (telitacicept), and a few others.

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for IgA Nephropathy. Currently, Travere Therapeutics is leading the therapeutics market with its IgA Nephropathy drug candidates in the most advanced stage of clinical development.

Leading Companies in the IgA Nephropathy Therapeutics Market Include
Pioneering companies, including Aravive, Aduro BioTech, Alnylam Pharmaceuticals, Chinook Therapeutics, Transcenta Holding, Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics, and many others, are actively engaged in developing novel drugs for potential market entry.

Emerging and Marketed IgA Nephropathy Therapies Covered in the Report Include
Some of the emerging therapies in the pipeline include Atrasentan (Chinook Therapeutics), Sparsentan (Travere Therapeutics), Narsoplimab (Omeros Corporation), TARPEYO/ KINPEYGO (budesonide) (Calliditas Therapeutics/STADA/Viatris/Everest Medicines), Iptacopan (Novartis Pharmaceuticals), BION-1301 (Chinook Therapeutics), and others.

Learn More About the Emerging Therapies and key Companies in the IgA Nephropathy Therapeutics Market @
https://www.delveinsight.com/sample-request/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. IgA Nephropathy Competitive Intelligence Analysis
4. IgA Nephropathy Market Overview at a Glance
5. IgA Nephropathy Background and Overview
6. IgA Nephropathy Patient Journey
7. IgA Nephropathy Epidemiology and Patient Population
8. IgA Nephropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. IgA Nephropathy Unmet Needs
10. Key Endpoints of IgA Nephropathy Treatment
11. IgA Nephropathy Marketed Products
12. IgA Nephropathy Emerging Therapies
13. IgA Nephropathy Seven Major Market Analysis
14. Attribute Analysis
15. IgA Nephropathy Market Outlook (7 major markets)
16. IgA Nephropathy Access and Reimbursement Overview
17. KOL Views on the IgA Nephropathy Market.
18. IgA Nephropathy Market Drivers
19. IgA Nephropathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.